Tigris names new chairman of the board

BONITA SPRINGS, Fla. A privately held drug maker that develops cancer treatments has appointed a new chairman of its board of directors.

Tigris Pharmaceuticals announced Thursday that it appointed Pedro Granadillo to the position. Granadillo has worked in the pharmaceutical industry for more than 30 years, including a term as SVP of Eli Lilly & Co., serving as on the Indianapolis-based drug maker’s executive committee and as head of human resources, manufacturing and quality.

“Pedro’s appointment as chairman of the board of directors will further expand his leadership role within our company and will play a key role in our partnering efforts and corporate strategy,” Tigris CEO Edmundo Muniz said in a statement. “We are pleased to have such a widely respected and experienced senior pharmaceutical executive chair our board of directors.”